Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
In the latest medical advances, Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma, has made significant strides in managing immune-checkpoint inhibitor toxicities in melanoma treatment.
In regulatory advancements, FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma. This quickened approval process suggests promising results in treatment efficacy.
A Novel Small Molecule has shown early activity in the treatment of pretreated multiple myeloma. This represents a potential new avenue in the fight against this cancer type.
In a comparison of treatment methods, proton and photon therapies are weighed against each other in terms of quality of life outcomes for oropharyngeal squamous cell carcinoma (OPSCC) patients in Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC.
Lastly, the key aspects of PSMA-directed imaging and radioligand therapy in treating prostate cancer are discussed in an article named 3 Things You Should Know About PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer.
